Skip to main content

Table 2 Data analysed for correlation with overall survival

From: Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

DC parameters

T cell parameters

DC (HLA-DR+ lin-) % of PBMC

CD8 + % of CD3+

BDCA-1+ DC % of total PBMC

Ki67+% of CD8 T cells

BDCA-2+ DC % of total PBMC

ICOS+% of CD8 T cells

BDCA-3+ DC % of total PBMC

Teff (HLA-DR+CD38+) % of CD8 T cells

BDCA-1+ % of DC

CD3+% of lymphocytes

BDCA-2+ % of DC

CD4+% of CD3+

BDCA-3+ % of DC

Ki67+% of CD4 T cells

BDCA-1+:BDCA-2+ ratio

ICOS+% of CD4 T cells

BDCA-1+:BDCA-3+ ratio

Treg+% of CD4 T cells

BDCA-2+:BDCA-3+ ratio

ki67 + % of Treg (CD25+CD127loFoxp3+)

BDCA-1+ DC CD40 MFI

ICOS + % of Treg (CD25+CD127loFoxp3+)

BDCA-1+ DC HLA-DR MFI

 

BDCA-2+ DC CD40 MFI

 

BDCA-2+ DC HLA-DR MFI

 

BDCA-3+ DC CD40 MFI

 

BDCA-3+ DC HLA-DR MFI

 
  1. List of parameters undergoing exploratory analysis for correlation with OS. Flow cytometry data was used to group patients above or below the median for each parameter, and repeated using data from each sample collection time point from baseline through to Cycle 3 Day 8
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us